Annovis Bio, Inc. announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson?s disease (PD). Topline data results are expected in January 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.36 USD | +22.04% | +56.26% | -55.29% |
05-10 | Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.29% | 75.43M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Annovis Bio, Inc. Announces Last Patient Last Visit in Phase III Study of Buntanetap in Parkinson?s Disease